The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
about
The role of EBV in the pathogenesis of Burkitt's Lymphoma: an Italian hospital based surveyALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literatureNon-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges AheadTrends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases.Outcome of children with B cell lymphoma in Venezuela with the LMB-89 protocol.Central nervous system disease in hematologic malignancies: historical perspective and practical applications.Burkitt lymphoma: epidemiological features and survival in a South African centrePrimary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG).Outcomes for children and adolescents with cancer: challenges for the twenty-first century.An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.Combination of dexamethasone, high-dose cytarabine, and carboplatin is effective for advanced large-cell non-Hodgkin lymphoma of childhood.Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.Clinical outcome of relapsed or refractory burkitt lymphoma and mature B-cell lymphoblastic leukemia in children and adolescents.Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi.Rasburicase: a potent uricolytic agent.Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies.Prognostic Value and Clinical Impact of (18)FDG-PET in the Management of Children with Burkitt Lymphoma after Induction Chemotherapy.Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children's oncology group report.Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience.Children's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution.Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective "Lymphomes Malins B" protocols. A Société Française des Cancers de l'Enfant study.Towards curative therapy in burkitt lymphoma: the role of early african studies in demonstrating the value of combination therapy and CNS prophylaxis.Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.Fertility preservation in girls.Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic lPrimary Burkitt lymphoma of the thyroid gland: case report of an exceptional type of thyroid neoplasm and review of the literature.Controversies in the treatment of Burkitt lymphoma in AIDSTreatment of Burkitt lymphoma in equatorial Africa using a simple three-drug combination followed by a salvage regimen for patients with persistent or recurrent diseaseContinuing challenges in childhood non-Hodgkin's lymphoma.Primary Orbital Lymphomatoid Granulomatosis in a 1-Year-Old ChildClinical course and prognostic factors of children with Burkitt's lymphoma in a developing country: the experience of a single centre in BrazilAdvances in paediatric cancer treatmentAutologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchChemotherapy-Induced Perforation of Gastric Burkitt Lymphoma; A Case Report and Review of the Literature.Burkitt lymphoma risk in U.S. solid organ transplant recipients.
P2860
Q21093165-C7546A9F-1BBD-4AA6-9262-967253A13856Q21198873-D8B03F88-A985-4800-9D4E-7D40CC78415CQ26797513-97152DBF-1D74-4E34-AD29-D1ED68A13CB9Q30540646-DE39D5BB-CDD2-4A0F-9DD7-D45A0C54D7ADQ33362735-B887BF97-F77E-4F97-B284-AEC57959EA62Q33585849-640037FD-BD1A-4010-8B69-08A3BCA4C21AQ33756475-D7DBBC9B-1263-44EC-A4FA-61758D4E9250Q33759495-05B5A770-1325-4C8F-80AF-F61ECD2CA2BCQ33897659-783A1D49-792C-41EE-A2A8-12A5E43A0F76Q34020070-7048AB93-AE54-4B6A-9947-96600AE6EA21Q34287195-13C2258E-6DB4-4F42-ABDD-0362FF828F6FQ34334050-02070CC9-D0E8-46FA-AFDD-3300A6E65A81Q34386029-90F5ABEB-4D47-4509-B129-3680DA43A19FQ34520470-CF5A67F3-87A6-4FAD-B35B-B5146B96DF58Q34588722-6D1304F0-9297-4AD8-AF76-25171C164E87Q34626802-62075D99-5C5C-4A56-B73E-DBBD11937E7FQ34931319-CDFA21ED-B5DE-4524-AFE8-C9AB31BB2826Q35011933-57483F6E-241D-4FAE-8655-EAADF98E0C80Q35067047-FC376179-CC73-4538-AA2B-5DBDE26E25A3Q35083003-61D1A7B9-8EBE-4ED7-BFD1-A9C2E770C03EQ35084407-265801FC-41B3-459D-803F-48EA3CA5AF48Q35204936-8FC79F70-E20E-47B0-A925-D30BCB8FD06EQ35616078-D0DD298E-FD3D-46FA-8996-401403B47902Q35667279-B58BE60A-14F3-476B-A688-B8A18DC0A237Q35669884-7AD16CE8-00FA-4F65-8848-87903499B066Q35687432-AAC26636-BEBB-4920-A18D-48C1A2F68C78Q35750976-74AF4DC1-56D2-43CA-9BE0-7780F591434AQ35750990-720E3A41-E760-4735-9B88-425E9A228A97Q35838156-9302CC25-0AC8-4536-A30F-CD5887E17F02Q35849907-C0D00867-1C08-4A89-8573-A996A8EB5C37Q36016608-C794593C-2880-4992-AABE-C18D950E0074Q36151295-D9B6387B-9835-44E6-9B2E-68FBB714DE1BQ36201443-492FA11B-5179-4FD2-9AD3-E137EE22A2D4Q36228057-1BC8A82D-4739-4F66-8967-4D2DD4EB999FQ36321254-C9922021-7530-4BD4-8240-E69029825A5BQ36364844-84E79476-3A7D-4F81-91DA-FD81A196E745Q36508630-A60AC9D8-D98C-46C4-A7A3-F6CC60A5EF4DQ36557201-C808E3D5-2F5D-4268-BF6F-37CB329D881FQ36631155-538783D9-B95F-4D88-995F-6E7D0A77C567Q36718143-B2B3F786-B604-4D7F-B22C-C19ACEF1F44E
P2860
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The Société Française d'Oncolo ...... ell lymphomas and L3 leukemia.
@en
The Société Française d'Oncolo ...... ell lymphomas and L3 leukemia.
@nl
type
label
The Société Française d'Oncolo ...... ell lymphomas and L3 leukemia.
@en
The Société Française d'Oncolo ...... ell lymphomas and L3 leukemia.
@nl
prefLabel
The Société Française d'Oncolo ...... ell lymphomas and L3 leukemia.
@en
The Société Française d'Oncolo ...... ell lymphomas and L3 leukemia.
@nl
P2093
P1433
P1476
The Société Française d'Oncolo ...... ell lymphomas and L3 leukemia.
@en
P2093
G Leverger
H Behrendt
M J Terrier-Lacombe
P304
P356
10.1182/BLOOD.V97.11.3370
P407
P577
2001-06-01T00:00:00Z